The ICN2's expertise lies at the nanoscale, where new properties, interactions, and ways to exploit them in everyday life are being discovered. Among its goals is to bring together scientists from diverse backgrounds in the pursuit of better science, better training, and better outreach to society while also seeking out new ways to engage with local and global industry.
ICN2 was accredited in 2014 as a Severo Ochoa Centre of Excellence, a recognition renewed in 2018 and 2023 for another 4-year period. The Severo Ochoa Programme, sponsored by the Spanish Ministry of Science, Innovation and Universities, aims to identify and support Spanish research centres that are among the world’s best in their specialty.
The objective is to commercialize the technologies developed in ICN2 (know-how, patents), with the ultimate goal of establishing long-term strategic relationships with companies for the commercialization of ICN2 technologies better orientated to real market needs.
En IDI ofrecemos soluciones técnicas integrales para sectores altamente regulados como el farmacéutico, veterinario, cosmético y químico. Combinamos experiencia, innovación y un enfoque basado en el análisis de riesgos para desarrollar proyectos seguros, eficientes y plenamente alineados con el cumplimiento normativo. Nuestro valor diferencial es una asistencia técnica cercana, experta y adaptada a cada cliente que combina la ingeniería farmacéutica con CQV de equipos e instalaciones.
Inbrooll Industries S.L. is a multidisciplinary engineering company specialized in the development of advanced technological devices, supporting clients from early concept to industrialization and production readiness.
Through its Indooit 360° methodology, Inbrooll ensures a structured and efficient development process, integrating electronics, mechanics, and microfluidics into robust and scalable solutions.
With a strong track record in healthcare, biotechnology, and scientific instrumentation, Inbrooll operates under ISO 13485, ISO 9001, and ISO 14001 certifications, guaranteeing high standards of quality and regulatory compliance.
Inbrooll acts as a strategic partner for companies seeking to transform innovative ideas into manufacturable and market-ready products.
We partner with MedTech, biotech and industrial companies developing new devices, helping them move efficiently from concept and prototyping to industrialization and production.
With a strong end-to-end approach and expertise in electronics, mechanics and microfluidics, we turn complex developments into robust, scalable and market-ready solutions—reducing risk and accelerating time to market under ISO 13485, ISO 9001 and ISO 14001 standards.
Innovamed Spain S.L. es una CMO especializada en inyección de plásticos en sala blanca ISO 7 que convierte ideas de dispositivos médicos en productos reales, listos para su industrialización y producción a escala.
Our goal is to establish long-term partnerships with medical device and MedTech companies, supporting them from design to industrialization as their trusted CMO partner.
From the Technology Transfer Office at the Institut Ciències del Mar (ICM-CSIC) we aim to connect our health technologies with industrial partners for licensing and joint value creation, while building collaborations to accelerate their path to market
The Foundation Institute for Bioengineering of Catalonia, is a research center conducting interdisciplinary research at the cutting edge of Knowledge in the bioengineering field to improve health and quality of life for people. We achieve our objective by offering our technological capabilities to companies, performing collaborative projects, licensing our inventions and setting up new spin offs.
Our Institute is a Center of Research Excellence as accredited by Spanish Government and a developer of the most innovative technologies with the capacity to transfer them to the market as accredited by the Catalonian Government. IBEC forms part of the alliances of selected research institutions BIST and CERCA institutes.
Our institute is formed by 23 groups with unique expertise in: Nano-robots, nanodevices, nanotechnology, Organ-on-a-chip, Organ and Tissue Biomimetics, Cell and Tissue engineering, 3D Bioprinting, Biomaterial, Biosensors, lab-on-a-chip, microfluidics, signal and data processing, and new therapies.
Asli Raman Martin Dombrowski
Senior Technology Transfer and Business Development Manager
Partnership Goal
Collaborations, offering biotechnology R&D services, out-licensing, seeking professional services and consulting
Partnering strategy/collaborations:
1) Offering to the industry technologies, Know-How and expertise
2) Offering out-licensing opportunities
3) Interested in R&D activities with companies
4) Interested in collaborative R&D activities
5) Industry in IBEC: Open Lab Opportunities
6) Interested in getting financial support to further develop the projects to reach the market
Zoi Melissari
Technology Transfer and Business Development Manager
Partnership Goal
Collaborations, offering biotechnology R&D services, out-licensing, seeking professional services and consulting
Partnering strategy/collaborations:
1) Offering to the industry technologies, Know-How and expertise
2) Offering out-licensing opportunities
3) Interested in R&D activities with companies
4) Interested in collaborative R&D activities
5) Industry in IBEC: Open Lab Opportunities
6) Interested in getting financial support to further develop the projects to reach the market
Eduardo Salas
Head of Technology Transfer and Business Development Office
Partnership Goal
Collaborations, offering biotechnology R&D services, out-licensing, seeking professional services and consulting
Partnering strategy/collaborations:
1) Offering to the industry technologies, Know-How and expertise
2) Offering out-licensing opportunities
3) Interested in R&D activities with companies
4) Interested in collaborative R&D activities
5) Industry in IBEC: Open Lab Opportunities
6) Interested in getting financial support to further develop the projects to reach the market
Integra Therapeutics is a biotechnology company pioneering the next generation of gene-writing tools to develop curative treatments for genetic, oncological, and autoimmune diseases with high unmet medical needs. By addressing the major technical bottlenecks in the Cell and Gene Therapy (CGT) space, we aim to improve the scope, efficiency, and safety of advanced therapies.
Our Technology: FiCAT Platform
At the core of our innovation is FiCAT (Find Cut and Transfer), a proprietary, state-of-the-art gene-writing platform engineered to overcome the main limitations of current gene therapies: payload size, integration precision, and genomic stability. FiCAT elegantly combines the pinpoint targeting precision of the CRISPR-Cas system with the highly efficient cargo transfer capabilities of an engineered piggyBac transposase. This unique mechanism allows for the safe and highly efficient targeted integration of both small and exceptionally large therapeutic DNA payloads into the genome.
Pipeline & Applications
Leveraging the versatility of the FiCAT platform, Integra Therapeutics is advancing a robust pipeline spanning both in vivo and ex vivo applications. Our development programs include a lead in vivo gene therapy project, alongside multiple highly promising ex vivo and in vivo cell therapy programs focused on next-generation CAR-T. By unlocking new possibilities in targeted DNA insertion, we are committed to delivering life-changing, durable genetic medicines to patients.
At Integra Therapeutics, we are actively seeking strategic alliances to maximize the therapeutic potential of the FiCAT platform. Our current partnering objectives are:
Strategic Co-Development Partnerships: We are seeking fully funded collaborations with leading pharmaceutical and biotechnology companies. Our goal is to leverage their clinical and commercial expertise to co-develop advanced therapies and validate the FiCAT platform through late-stage clinical trials.
Platform Out-Licensing: We offer flexible licensing agreements for the FiCAT technology. We aim to empower industry partners by integrating our highly precise, large-payload gene-writing capabilities into their proprietary Cell & Gene Therapy (CGT) pipelines.
Synergistic R&D Collaborations: We are open to early-stage collaborations, including in vitro and in vivo feasibility studies, to further validate FiCAT technology across novel delivery systems, cellular contexts, and therapeutic indications. We are also receptive to forming consortiums with academic and industry leaders to jointly apply for large-scale public and private translational grants.
Inteplast Medical, a division of Inteplast S.A., specializes in the design and manufacture of high-quality plastic solutions for the medical, pharmaceutical, and veterinary sectors. With over 50 years of experience and facilities in Spain and the Czech Republic, we operate a 1,500 m² ISO Class 8 clean room in Catalonia. Our capabilities include thermoplastic injection molding, overmoulding, bi-material injection, and final product assembly. Production is carried out under a sanitary license validated by AEMPS. We offer integrated, customized solutions, supporting our clients from concept to industrialization while ensuring compliance with the highest technical and regulatory standards.
Inveniam is a specialized strategic consulting and financial advisory firm supporting technology-driven companies and researchers. The firm focuses on Life Sciences, GenAI & Computation and Resource Sustainability sectors. Inveniam provides end‑to‑end support across technology transfer, corporate finance, and public funding. Through tailored, hands‑on advisory, Inveniam helps innovators bring breakthrough technologies to market with measurable impact.
I would like to find relevant new technologies that solve urgent unmet medical needs, to explore whether or not Inveniam can help move it forward towards patients.
Inveready is a leading Spanish financial services firm anchored in its alternative funds expertise and complemented with wealth management services and our proprietary public investment funds.
Senior Technology Transfer and Business Development Manager
